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Abstract
Objective: A high level of cerebrospinal fluid (CSF) neopterin is a marker of central nervous system inflammatory-immune
mediated processes. We aimed to assess data from 606 neuropediatric patients, describing the clinical and biochemical
features of those neurological disorders presenting CSF neopterin values above a new cut-off value that was defined in our
laboratory.
Methods: To establish the new CSF neopterin cut-off value, we studied two groups of patients: Group 1 comprised 68
patients with meningoencephalitis, and Group 2 comprised 52 children with a confirmed peripheral infection and no central
nervous system involvement. We studied 606 CSF samples from neuropediatric patients who were classified into 3 groups:
genetic diagnosis (A), acquired/unknown etiologic neurologic diseases (B) and inflammatory-immune mediated processes
(C).
Results: The CSF neopterin cut-off value was 61 nmol/L. Out of 606 cases, 56 presented a CSF neopterin level above this
value. Group C had significantly higher CSF neopterin, protein and leukocyte values than the other groups. Sixteen of
twenty-three patients in this group had a CSF neopterin level above the cut-off, whereas three and seven patients
presented increased leukocyte and protein values, respectively. A significant association was found among CSF neopterin,
proteins and leukocytes in the 606 patients. White matter disturbances were associated with high CSF neopterin
concentrations.
Conclusions: Although children with inflammatory-immune mediated processes presented higher CSF neopterin values,
patients with other neurological disorders also showed increased CSF neopterin concentrations. These results stress the
importance of CSF neopterin analysis for the identification of inflammatory-immune mediated processes.
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Introduction
Neopterin is a pterin containing a 2-amino-4-oxo-pyrazine-
pyrimide (pterin) ring and is formed from guanosine-triphosphate
in the synthetic pathway of tetrahydrobiopterin (BH4) [1]. BH4
acts as a cofactor in the rate-limiting enzymatic step of dopamine
and serotonin biosynthesis (hydroxylation of tyrosine and trypto-
phan) [2]. It also acts as a cofactor in the hydroxylation of
phenylalanine to tyrosine [3] and plays a role in the inducible
nitric oxide synthase reaction [2]. Moreover, neopterin is a direct
response to T-helper cell 1 stimulation by interferon-c [4], [5], the
central cytokine involved in the activation of the cellular immune
system. Therefore, neopterin is a sensitive indicator in immune-
mediated and inflammatory disorders [1], [6]. Its concentration in
biological fluids may be useful for the diagnosis of inflammatory
and immune-mediated diseases in which T-helper cell 1 and
macrophages are involved [2], [6], [7]. It is also useful for the
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diagnosis of several genetic conditions affecting BH4 biosynthesis
and neurotransmitter pathways [8], [9].
Age-matched reference values for CSF neopterin in the
pediatric age have scarcely been reported [2], [10], [11], [12]
and have been directed towards detecting inborn errors of BH4
metabolism. Increased CSF neopterin concentrations have been
described in children with bacterial meningitis [13], viral
encephalitis, febrile convulsions, cryopyrin-associated periodic
syndrome [14], Aicardi-Goutie`res syndrome [12], opsoclonus-
myoclonus [15] and infantile epileptic encephalopathies [16].
Therefore, assessing the CSF neopterin values in a cohort of
patients with central nervous system (CNS) inflammatory or
immune-mediated diseases seems important as a first step to
establish new cut-off values that may indicate when a patient may
present an inflammatory-immune event. Furthermore, many
pediatric neurological patients end up having a syndromic
diagnosis of unknown etiology after extensive metabolic studies
[17]. In some of these patients, the presence of high CSF neopterin
values might indicate inflammatory-immune mediated processes
in the CNS, facilitating the differential diagnosis of other
neurometabolic and neurogenetic conditions.
We aimed to establish a new CSF neopterin cut-off value using
a cohort of patients with CNS immune-mediated diseases. After
defining this new value, we assessed the data from a cohort of 606
neuropediatric patients and described the clinical and biochemical
features of those neurological disorders presenting high CSF
neopterin values.
Materials and Methods
Ethics Statement
All samples from the patients were obtained in accordance with
the 2000 revised Helsinki Declaration of 1975. The study was
approved by the local ethics committee review board, named
‘‘Comite` E`tica Investigacio´ Clı´nica’’ from Sant Joan de De´u
Foundation. All parents or guardians on behalf of the participants
provided the written informed consent to participate in this study.
Material and methods
We previously established reference values for CSF neopterin
concentrations in a cohort of 116 pediatric patients in whom viral
or bacterial meningitis, encephalitis and other neurological
conditions of non-metabolic origin were ruled out [11]. In that
study, no differences were observed in patients older than one
month, whose upper limit reference interval for neopterin was
established as 34 nmol/L, very similar to that previously reported
[6], [10]. To establish the new CSF neopterin cut-off value, we
studied two groups of patients, all of them older than one month of
age. Group 1 comprised 68 patients (45 males, 23 females, mean
age 6.5 years, standard deviation [SD] 5 years, median age 5.2
years, range 1 month–19 years, Table 1) with viral (n = 54) and
bacterial meningoencephalitis (n = 14). Confirmed microbiological
diagnoses were achieved by specific polymerase chain reaction and
bacterial culture methods according to routine standardized
procedures. Among the viral meningoencephalitis patients, the
main agents were Herpesviruses (n = 4) and Enteroviruses (n = 24).
The remaining patients in this subgroup (26/54) had lymphocytic
meningoencephalitis under investigation. Regarding bacterial
infections, Streptococcus pneumoniae (n = 8) and Neisseria meningitides
(n = 6) were responsible for the disease. White blood cell (WBC),
glucose and protein levels in the CSF were analyzed for each
sample (all cases showed WBC counts higher than 5 cells/mm3).
We excluded those samples with elevated WBC counts attributable
to contamination with blood after a corrective formula was applied
[18]. Group 2 comprised 52 children (40 males, 12 females, mean
age 8 months; SD 12 months; median age 5.4 months, age range:
1 month–6 years, Table 1) with confirmed viral (n = 15) or
bacterial (n = 37) peripheral infections without CNS involvement.
Neurologic cohort of patients
Between January 2001 and April 2012, 852 CSF samples were
analyzed in the Sant Joan de De´u Hospital Laboratory. The
samples were collected from patients afflicted by several neuro-
logical disorders for which a diagnostic lumbar puncture was
indicated. Of the initial group of samples, 242 were excluded for
one of the following reasons: traumatic (hematic) puncture and
inadequate conditions for sample collection and preservation, such
as the lack of rostral-caudal gradient sampling, inappropriate
temperature or lack of light protection. Finally, 606 samples (mean
age: 4.5 years; SD 4.7 years; age range: 0.16–18 years; sex: 52.6%
males) were included in the study and were classified into three
different clinical groups: A) patients with confirmed genetic
diseases (n = 160), including inborn errors of metabolism of simple
and complex molecules, mitochondrial diseases and neurogenetic
disorders; B) patients with acquired neurologic disorders (n = 423),
including ischemic and hemorrhagic injuries, neurological disor-
ders with motor disturbances, mental retardation plus other
neurological signs and psychiatric conditions, leukodystrophy and
malformations, epilepsy and epileptic encephalopathies; and C)
patients with inflammatory or immune-mediated diseases (n = 23),
including Aicardi-Goutie`res syndrome, acute disseminated en-
cephalomyelitis, Guillain Barre´ syndrome, anti-NMDA (N-methyl
D-aspartate) receptor encephalitis, chronic infantile neurological,
cutaneous and articular syndrome, histiocytosis, myasthenia gravis
syndrome and brain parasitosis. Detailed information about the
diagnoses of the entire cohort is available upon request. Their
main clinical and CSF biochemical data are presented in Tables 2
and 3.
Laboratory studies
In the 606 patients, screening laboratory tests for the diagnosis
of metabolic and genetic diseases (lactate, ammonium, amino
acids, organic acids, acylcarnitines, glycosaminoglycans, sialo-
transferrin, fatty acids and karyotype) were performed when
indicated, using standard procedures. CSF samples were collected
by lumbar puncture as previously reported [11].Neopterin and
biopterin determinations were performed by fully oxidation of all
isophorms of pterins by MnO2. Both total pterins were analyzed
by reverse phase high performance liquid chromatography with
fluorescence detection following a previously reported procedure
[11]. Briefly, the mobile phase consisted of 1 mmol/l potassium
phosphate plus methanol (95/5 v/v). Excitation was 350 nm, and
emission was 450 nm. Glucose and proteins were analyzed with
standard automated spectrometric procedures. WBCs were
counted in a manual counting chamber using undiluted CSF.
The differential analysis of WBCs was only performed upon
increased CSF WBC counts, and the cells were classified into
polymorphonuclear and mononuclear leukocytes. The reference
values were 70–109 mg/dL (3.9–6.1 nmol/l) for CSF glucose,
below 40 mg/dl for proteins and below 5 cells/mm3 for WBCs.
Statistics
All analyses were performed using the SPSS 19.0 software. To
establish the new CSF neopterin cut-off, COR curve analysis was
applied. The Kolomogorov-Smirnow test was applied to assess the
data distribution. Because the data did not follow a Gaussian
distribution, different non-parametric tests were applied. The
Mann-Whitney U test was used to test for the statistical
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significance of different CSF variables in Groups 1 and 2. In the
entire sample (n = 606), the Spearman correlation test was applied
to search for correlations between the CSF neopterin level and the
other variables studied in the CSF (biopterin, proteins, leucocytes,
glucose) and age. To compare the CSF neopterin level with the
other CSF variables among the different clinical groups, the
Kruskal-Wallis test was applied. To describe whether high CSF
neopterin values were associated with a significantly higher risk of
having altered CSF proteins (.40 mg/dl), altered CSF leucocytes
(.5 cells/mm3), white matter disturbances or the presence of
epilepsy, we applied the Chi-square test and computed the Odds
ratio for each group. Statistical significance was defined as
p,0.05.
Results
To establish the CSF neopterin cut-off value, a ROC curve
between groups 1 (central infections) and 2 (peripheral infections)
was created. The best discrimination was provided by the CSF
neopterin value of 61 nmol/L (AUC = 0.934, range: 0.883–0.985)
with a sensitivity of 91.3% and specificity of 88.5% (Figure 1).
Table 1 shows the results of the different CSF laboratory variables
analyzed in groups 1 and 2. Significant differences were observed
between groups 1 and 2 for all CSF variables (Mann-Whitney U
test, p,0.001 for CSF WBC, p,0.001 for CSF neopterin,
p = 0.038 for CSF glucose and p,0.001 for CSF proteins).
Neurologic cohort of patients: In the 606 patients, a significant
positive correlation was observed for CSF neopterin with CSF
proteins (r = 0.178, p,0.001) and leukocytes (r = 0.148, p,0.001)
but not with CSF glucose, CSF biopterin and patient age. Given
this last finding, a unique age group of patients was considered for
subsequent analysis.
Figure 2 shows the distribution of the 606 neurological patients
according to three clinical groups and the percentages of patients
with high CSF WBC (.5 cells/mm3), high CSF proteins
(.40 mg/dL) and high CSF neopterin concentrations
(.61 nmol/L). In all groups, the proportion of patients with high
CSF neopterin levels was higher than that of high CSF WBC. Of
these 606 patients, 56 presented with increased CSF neopterin
values according to the 61 nmol/L cut-off value (Table 2). The
inflammatory-immune mediated group (n = 23) had significantly
higher CSF neopterin values (X2 = 35.01, p,0.001), CSF proteins
(X2 = 12.71, p = 0.002) and CSF leukocytes (X2 = 6.23, p = 0.044)
compared with the other groups. Moreover, in this group, up to
69.6% of the patients (16 out of 23) had CSF neopterin
.61 nmol/l. In contrast, among these 16 patients, three had
increased WBC, and seven presented increased proteins (Table 2).
Considering the seven patients with CSF neopterin values below
Table 1. CSF biochemical values from subjects with CNS infections and peripheral infections.
Medical Diagnosis N
CSF Neopterin (nmol/L)
median (range)
CSF proteins (mg/mL)
median (range)
CSF leukocytes (WBC/
mm3) median (range)
CSF glucose (nmol/L)
median (range)
Viral meningitis 54 159.5 (46–844) 37 (15–499) 92.5 (9–2000) 3.24 (2.48–4.73)
Bacterial meningitis 14 265 (18–1368) 126.5 (14–490) 242.5 (10–18380) 2.14 (0.28–3.58)
Total Group 1 (Interval age 1 mo–19 y) 68 167 (18–1368)* 40.5 (14–499)* 100 (9–18320)* 3.21 (0.28–4.73)*
Viral peripheral infection 15 45 (23–193) 30 (4–61) 0 (0–15) 3.21 (2.7–4.18)
Bacterial peripheral infection 37 28 (8–282) 19 (10–99) 0 (0–40) 3.57 (2.37–6.33)
Total Group 2 (Interval age 1 mo–6 y) 52 34.5 (8–282)* 21 (10–99)* 0 (0–40)* 3.41 (2.37–6.33)*
*Significant values were observed in Total Group 1 vs Total Group 2 (U-Mann Whitney test). The data for the CSF variables are shown as median and range in brackets.
CSF: cerebrospinal fluid, WBC: white blood cells.
doi:10.1371/journal.pone.0083237.t001
Table 2. Patients with CSF neopterin levels above 61 nmol/l (n = 56).
Clinical groups (patients
NP.61 nM/total patients
group) Diagnosis CSF NP (nmol/l)
CSF proteins
(mg/dl)
CSF leukocytes
(WBC/mm3)
Patients with
altered
proteins
Patients with
altered
leucocytes
A. Genetic diseases
(n = 10/160, 6.2%)
8 mitochondrial dis., 1 ARCI
syndrome, 1 VLCAD def.
68.7 (62.6–153) 26 (16–113) 0 (0–5) 2/10 0/10
B. Acquired neurologic
disorders without inflam-
matory suspicion
(n = 30/423, 7.1%)
12 epilepsies, 2 epileptic
encephalopathy, 9 white matter
dist., 4 motor dist., 2 strokes,
2 necrosis, 1 mental disorder.
97 (61–486) 22 (11–459) 0 (0–70) 4/30 1/30
C. Inflammatory/immune-
mediated diseases
(n = 16/23, 69.6%)
9 AGS, 3 encephalitis, 1 Anti-
NMDA enceph., 1 CINCA sd,
1 brain parasitosis, 1 histiocytosis
238 (67–3010)* 33 (16–447)* (0–30)* 7/16 3/16
Total patients (n = 56/606) 13/56 4/56
*Inflammatory/immune-mediated group had significantly elevated CSF neopterin (X2 = 35.01, p,0.001), CSF proteins (X2 = 12.71, p = 0.002) and CSF leukocytes
(X2 = 6.23, p = 0.044) compared with the other groups. Moreover, up to 69.6% of the patients more frequently had CSF NP.61 nmol/L. Out of 56 patients with a CSF
neopterin level above 61 nmol/l, 13 patients had altered CSF proteins and four had altered CSF leucocytes.
AGS: Aicardi-Goutie`res syndrome; ARCI: arthrogryposis, renal tubular dysfunction, cholestasis, ichthyosis syndrome; anti-NMDA encephalitis: anti-(N-methyl D-aspartate)
receptor encephalitis; CINCA: chronic infantile neurological, cutaneous and articular syndrome; VLCAD: very long-chain acyl-CoA dehydrogenase; CSF NP: cerebrospinal
fluid neopterin; WBC: white blood cells. Dist: disturbances. The results are shown as the median and interval in brackets.
doi:10.1371/journal.pone.0083237.t002
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61 nmol/L, one presented increased CSF WBC, and three had
increased CSF proteins (Table 3). The etiological diagnoses of
these 23 patients are presented in Tables 2 and 3. Remarkably,
groups A and B showed a relatively high percentage of patients
with increased CSF neopterin levels, with some overlapping with
those values found in the group of inflammatory-immune
mediated processes (group C, Table 2). Table 3 presents the
clinical diagnoses and biochemical findings of the 550 patients
with CSF neopterin ,61 nmol/l. The proportion of patients with
high CSF proteins and high CSF WBC was 68/550 and 9/550,
respectively. No differences were observed among the three
clinical groups for the different CSF biochemical parameters.
Finally, we explored whether increased CSF neopterin
(.61 nmol/L) could be related to a significantly higher risk of
having high CSF proteins (.40 mg/dl), high CSF WBC
(.5 cells/mm3), white matter disturbances or the presentation of
epilepsy. The odds ratio showed a significant association between
high CSF neopterin and high CSF proteins in the entire patient
Table 3. Patients with CSF neopterin levels below 61 nmol/l (n = 550).
Clinical groups (patients NP.61 nM/total
patients group) CSF NP (nmol/l)
CSF proteins
(mg/dl)
CSF leukocytes
(WBC/mm3)
Patients with
altered proteins
Patients with
altered
leucocytes
A. Genetic diseases (n = 150/161, 92.9%) 14.05 (4.1–60) 20 (4–305) 0 (0–10) 18/150 5/150
Neurologic disorders without inflammatory
suspicion (n = 393/422, 93.8%)
14 (3.10–57.5) 21 (1–226) 0 (0–169) 47/393 3/393
Inflammatory/immune-mediated disease
(n = 7/23, 30.4%)
15 (11.80–36.3) 39 (15–170) 0 (0–75) 3/7 1/7
Total patients (n = 550/606) 68/550 9/550
Out of 550 patients with CSF neopterin levels below 61 nmol/l, 68 patients had altered CSF proteins, and nine had altered CSF leucocytes. CSF NP: cerebrospinal fluid
neopterin. The results are shown as the median and interval in brackets.
doi:10.1371/journal.pone.0083237.t003
Figure 1. ROC curve to determine the new CSF neopterin cut-off. The samples were classified into two groups according to the condition
that they presented either bacterial/viral central infection (n = 68) or peripheral infection (n = 52). The area under the curve was 0.934 (range: 0.883–
0.985) with 61 nmol/l as the new cut-off. The sensitivity was 91.3%, and the specificity was 88.5%.
doi:10.1371/journal.pone.0083237.g001
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cohort (1.95-fold higher, CI 95% = 1.1–3.48, p = 0.026) and
increased WBC count (3.39-fold higher, CI 95% = 1.44–7.98,
p = 0.028). The risk of having alterations in white matter with CSF
neopterin .61 nmol/L was only observed in group B (2.30-fold
higher, CI 95% = 1.72–3.07, p,0.001). Conversely no increased
risk of having epilepsy with CSF neopterin above 61 nmol/l was
observed in any group. Additionally, there was no significant risk
of having high CSF proteins, high CSF leukocytes, white matter
disturbances or epilepsy when the CSF neopterin level was below
61 nmol/L.
Discussion
Neopterin is released in the first step of the BH4 biosynthetic
pathway, which is controlled by the GTP cyclohydrolase I enzyme
[1]. Some inflammatory cytokines, mainly interferon-c, selectively
stimulate this enzyme in macrophages, leading to the accumula-
tion and excretion of high levels of neopterin in the body fluids of
patients with inflammatory or immune-mediated processes [12],
[19]. It is known that there is an intrathecal synthesis of neopterin
by microglia, which constitutes the innate immune cells of the
CNS [2], [20]. As the blood-brain barrier has a low permeability
for peripheral neopterin [2], the study of CSF neopterin may be a
useful tool for the diagnosis of the inflammatory-immune central
processes not being altered by peripheral inflammatory processes.
To our knowledge, no CSF neopterin cut-off values to identify
specific immune-mediated processes have been previously estab-
lished. Moreover, data regarding the evaluation of CSF neopterin
values in large cohorts of neurological patients have scarcely been
reported [6], [21]. In our previous study [11] we found a
statistically significant correlation between CSF neopterin and age
in children younger than one month of age. Thus before starting
the present study, we excluded all patients younger than one
month of age. We established a CSF neopterin cut-off value of
61 nmol/L through the analysis and comparison of two cohorts of
patients with and without confirmed CNS inflammatory-immune
mediated processes. As it is known, during the early postnatal life
there is a great variation in neuronal network formation, in blood-
brain barrier stability and in amounts of neurotransmitters
modulators [11], [22] leading to greater CSF neopterin values.
We are concerned about the different mean age of both groups
studied (6.5 years versus 8 months) and the possibilities of bias in
our results due to those normal age-related changes in CSF
neopterin. To test whether the difference in age had effect on the
cut-off, we did two COR curves studies. One COR curve that
included 1-month to 1-year-old patients (data not shown) and
another one that contained 1-month to 19-years old patients
(present COR curve). We obtained two cut-off values with very
similar sensibility and specificity. That finding and the lack of
correlation between CSF neopterin with the age in the 606
neurological patients corroborated the limited influence of the age
in CSF neopterin values in our study. The newly established cut-
off value was higher than the upper limit of most published
reference intervals for neopterin, which are mainly clustered
between 20–34 nmol/L [6], [10], [11], [12].
Interestingly, 56/606 neurological patients showed neopterin
levels higher than 61 nmol/L. This observation was remarkable as
most of these patients were not under suspicion of having an
immune-mediated process (except for some of the 23 cases with
inflammatory diseases). In contrast, if the former upper limit of
CSF neopterin (34 nmol/L) would have been used, 87 out of 606
patients would have shown neopterin values above the normal
Figure 2. Representation of the 606 neurological patients in the clinical groups. Each group shows the percentage of patients with high
CSF WBC, high CSF proteins and high CSF neopterin. The inflammatory/immune-mediated group had a significantly elevated percentage of high CSF
WBC (*X2 = 27.91, p,0.001), high CSF proteins (YX2 = 17.51, p,0.001) and high CSF NP (WX2 = 103.73, p,0.001) compared with the other groups.
doi:10.1371/journal.pone.0083237.g002
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range. Using this approach, the number of patients seems
excessive because most of them belonged to clinical categories
with no evidence of immune-mediated processes, such as
neurometabolic diseases (data not shown). Nevertheless, only one
case belonging to the inflammatory-immune mediated group
presented a CSF neopterin value between 34 and 61 nmol/L. In
all likelihood, with the application of this new cut-off value, a
better discrimination between inflammatory-immune mediated
conditions and other neurological conditions will be achieved.
This discrimination may be critical for etiological diagnosis and
therapeutic options because treatment strategies may be com-
pletely different in these categories.
Only a previous study about CSF neopterin values in
neurological patients was published [6]. In that study, 158 cases
were analyzed and grouped according to the mode of presentation
and subsequent evolution of disease. We grouped our neurological
patients according to whether they had a genetic, acquired or
unknown etiologic neurologic disease or inflammatory-immune
mediated process. This classification allowed us to identify which
clinical groups had CSF neopterin values above the cut-off value.
As expected, CSF neopterin was significantly elevated in the group
of inflammatory-immune mediated processes [12]. However, 7 out
of 23 patients in this group showed normal neopterin values, and
the WBC and protein values were even less frequently altered
(Tables 2 and 3), supporting the higher specificity and sensitivity of
neopterin analysis compared with WBC and proteins, as
previously suggested [6]. The relapsing course of these diseases
and the normal cytokines and other immune biomarkers reported
for patients with Aicardi-Goutieres syndrome [12] and some
encephalitis [2], [6], [23] would explain these findings. Interest-
ingly, patients from the other clinical groups also showed increased
CSF neopterin values, with CSF protein and WBC being less
frequently impaired than neopterin.
Concerning the neurological patients with genetic diseases, ten
cases showed CSF neopterin levels moderately above 61 nmol/L
(eight being patients with mitochondrial diseases). This subtle
elevation most likely reflected inflammatory events associated with
CNS damage [6] as these eight patients presented white matter
disturbances (n = 2), brain atrophy (n = 1) and basal ganglia
abnormalities (n = 5). The neurologic patients with other genetic
diseases showed mostly normal neopterin concentrations given
that no immune-mediated processes are present in these disorders,
supporting the specificity of the analysis.
Regarding the patients with acquired neurologic disorders or
with unknown etiology, although the percentage of patients with
high CSF neopterin was quite similar to that of group A (7.1%
versus 6.2%), some patients showed values in the range of
inflammatory-immune-mediated diseases (Table 2). In these
patients, the diagnostic orientation changed after neopterin
analysis from a metabolic or a genetic disorder to an immune-
mediated process.
White matter abnormalities on MRI were associated with CSF
neopterin levels above 61 nmol/L in the group B patients. These
results may be explained because neopterin is also produced
intrathecally by different glial brain cells, acting as a possible link
among inflammation, neurodegeneration and regeneration [24],
[25]. These events can be found in primary inflammatory
processes but are also commonly involved in some neurological
acquired and unknown etiology diseases, in which neuroimaging
reflects CNS damage. Stroke, epilepsy [16] and ischemia [20] are
different processes that may generate hypoxia and production of
reactive oxygen species leading to activation of inflammatory
cascade. These inflammatory products and oxidative stress not
only release proinflammatory cytokines but also alter the
permeability of the blood-brain barrier, produce the disruption
of neuronal-microgial interaction and increases in extracellular
glutamate. All of these events may explain the high CSF neopterin
values in patients belonging to Group B [20]. Furthermore, these
patients would be candidates to receive a therapeutic assay with an
anti-inflammatory treatment. In group B, no increased risk of
having epilepsy was observed in the patients with neopterin
.61 nmol/L. However, approximately 50% of the patients
(table 2) with high neopterin presented with epilepsy. This matter
deserves further investigation as a relationship between epilepsy
and inflammation in the CNS has been previously reported [16]
with a worse prognosis in patients presenting with epilepsy and
increased neopterin [16].
Concerning patients with neopterin levels below 61 nmol/L
(n = 550), nine patients showed increased WBC, and 66 showed
increased proteins. Furthermore, in groups B and C, there was a
clear difference between the percentage of patients with high CSF
neopterin and those with high CSF WBC (figure 2), supporting the
high sensitivity of the neopterin values. However, the CSF protein
concentrations were frequently increased, most likely reflecting
other pathophysiological phenomena in addition to immune
events, such as brain injuries by vascular events [26] and increased
blood-brain barrier permeability in energy metabolism disorders
[27]. This finding would explain the relatively high percentage of
increased CSF proteins compared with increased CSF WBC.
Further evidence for neopterin as a good inflammatory biomarker
was the association of its increased CSF values with a higher risk of
having alterations in both WBC counts and protein concentration.
This fact is important for the clinical practice since these two
markers are the most commonly applied for diagnosis of
inflammatory/immune events in clinical laboratories
Conclusion
This report is the first to establish a new CSF neopterin cut-off
value to detect inflammatory and immune-mediated neurological
disorders. This new value was higher than the upper-limit of the
reference intervals previously established. Although the group of
patients who more frequently present high CSF neopterin values
was that with immune-inflammatory processes, patients with other
neurological disorders had CSF neopterin values above the new
cut-off value in a noticeable percentage of cases. Therefore, this
value was not only useful to detect the presence of an immune-
mediated process but also because the possibility of an anti-
inflammatory treatment may arise.
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